This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Neuroendocrine tumors

CD56

Patient sample and mouse studies suggest CD56+ NK cells could help treat neuroblastoma. In vitro, peripheral blood mononuclear cells from healthy donors were selected for cell surface CD56 expression, mixed 1:1 with CD56- cells and then activated using a combination of IL-12, IL-15 and a CD3 antibody. In xenograft mice with neuroblastoma cell lines, the activated mixture decreased tumor growth compared with nonactivated NK cells or no treatment. Next steps include a clinical trial of the cells in patients with neuroblastoma.

SciBX 6(11); doi:10.1038/scibx.2013.263
Published online March 21, 2013

Patent and licensing status undisclosed

Rujkijyanont, P. et al. Cancer Res.; published online Feb. 25, 2013;
doi:10.1158/0008-5472.CAN-12-3322
Contact: Wing Leung, St. Jude Children's Research Hospital, Memphis Tenn.
e-mail:
wing.leung@stjude.org